Neuravi Hires Exec to Lead U.S. Commercialization of Stent Retriever

Neuravi, a company focused on improving clinical outcomes for stroke patients, has added Robert Colloton to the company’s senior management team as vice president of U.S. sales and marketing.
 
Colloton brings 25 years of experience in medical device sales and market development and branding expertise, with a deep understanding of the neurovascular market in particular. Most recently, he was vice president of marketing and sales at Revision Optics. Previously, he served as vice president of global sales and marketing at Micrus Endovascular, where he built the sales team and grew the business to become a leading player in aneurysm therapy. He also held senior leadership positions in sales and marketing at VNUS Medical Technologies Inc., TransVascular Inc., and Cardiometrics Inc.
 
“We are excited to bring our stroke therapy to physicians in the United States. Enrollment in our ARISE II clinical study of the EmboTrap Revascularization Device is progressing ahead of our plan, so this is the right time for Neuravi to invest in building the leadership team for our U.S. program,” said Eamon Brady, CEO. “Bob truly understands this market and the needs of the neurointerventionalists, and he shares our passion for delivering value and striving for excellence. We are thrilled to welcome him to the Neuravi family.”
 
The design of Neuravi’s EmboTrap Revascularization Device is informed by extensive research on the wide range of different clot types that cause ischemic stroke. With this foundation of research, the EmboTrap platform is engineered to restore blood flow to the brain by retrieving and retaining clot with a proprietary dual-layer stent-like structure. The device’s integrated distal protection zone is designed to reduce the risk of clot fragmentation during retrieval, which could cause additional harm to the patient.
 
The ARISE II study is an international clinical trial assessing the safety and effectiveness of EmboTrap, and it will enroll 210 patients in up to 30 sites across the United States and Europe. Data from the trial will support a U.S. Food and Drug Administration (FDA) submission for approval to market the device in the United States.

Adoption of endovascular stroke therapy procedures is growing significantly since compelling data from multiple large-scale randomized trials last year confirmed the value of using stent-retriever thrombectomy to rapidly clear occlusive clot from large cerebral vessels.

“I’m eager to be re-entering the neurovascular market, especially at this exciting time of tremendous growth in acute ischemic stroke treatment,” said Colloton. “Neuravi made the gutsy decision early on to take the time to invest in understanding the science of the clots that cause strokes before developing a solution. I’m inspired by the dedication of the team, and I look forward to working with neurointerventionalists to help advance stroke treatment for patients in the U.S.”
 
The EmboTrap Revascularization Device is available in Europe to treat patients with acute ischemic stroke. The EmboTrap is currently available for investigational use only in the United States under the ARISE II clinical trial.
 
Neuravi designs, develops and manufactures acute stroke treatment devices. Through its investment in the Neuravi Thromboembolic Initiative (NTI), Neuravi supports collaboration between engineers, clinicians and researchers to deepen the understanding of clot and occlusion dynamics to improve patient outcomes in stroke.